mirvetuximab
Immunogen
['congrat', 'ovarian']
mirosol data demonstrating the first improvement in overall survival in platinum resistant ovarian cancer. 12.8 vs 16.5 months with mirvatuximab #practicechanging #newstandard congrats to dr. katie moore and all the investigators. #asco2023 
Univ of Mississippi, Director of Cancer Center & Research Institute// Gyn Onc// Tweets are mine.